CTLA-4 downregulates T-cell activation and inhibits its anti-tumor immune response by binding to co-stimulatory molecules on DCs (CD40, CD80, and CD86) and suppressing their ability in presenting foreign or tumor antigens [60]. This evidence concerns the gene CD80 and neoplasm.